PMID- 26362631
OWN - NLM
STAT- MEDLINE
DCOM- 20160203
LR  - 20220409
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Print)
IS  - 0009-7322 (Linking)
VI  - 132
IP  - 16
DP  - 2015 Oct 20
TI  - Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance 
      in Cardiac Amyloidosis.
PG  - 1570-9
LID - 10.1161/CIRCULATIONAHA.115.016567 [doi]
AB  - BACKGROUND: The prognosis and treatment of the 2 main types of cardiac 
      amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) 
      amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular 
      magnetic resonance with late gadolinium enhancement (LGE) is a reference standard 
      for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk 
      is unknown. METHODS AND RESULTS: Two hundred fifty prospectively recruited 
      subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 
      119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic 
      resonance. Subjects were followed up for a mean of 24+/-13 months. LGE was 
      performed with phase-sensitive inversion recovery (PSIR) and without (magnitude 
      only). These were compared with extracellular volume measured with T1 mapping. 
      PSIR was superior to magnitude-only inversion recovery LGE because PSIR always 
      nulled the tissue (blood or myocardium) with the longest T1 (least gadolinium). 
      LGE was classified into 3 patterns: none, subendocardial, and transmural, which 
      were associated with increasing amyloid burden as defined by extracellular volume 
      (P<0.0001), with transitions from none to subendocardial LGE at an extracellular 
      volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 
      0.55 (AL) and 0.47 to 0.59 (ATTR). Sixty-seven patients (27%) died. Transmural 
      LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 2.1-13.7; 
      P<0.0001) and remained independent after adjustment for N-terminal pro-brain 
      natriuretic peptide, ejection fraction, stroke volume index, E/E', and left 
      ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3-13.1; 
      P<0.05). CONCLUSIONS: There is a continuum of cardiac involvement in systemic AL 
      and ATTR amyloidosis. Transmural LGE is determined reliably by PSIR and 
      represents advanced cardiac amyloidosis. The PSIR technique provides incremental 
      information on outcome even after adjustment for known prognostic factors.
CI  - (c) 2015 The Authors.
FAU - Fontana, Marianna
AU  - Fontana M
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Pica, Silvia
AU  - Pica S
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Reant, Patricia
AU  - Reant P
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Abdel-Gadir, Amna
AU  - Abdel-Gadir A
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Treibel, Thomas A
AU  - Treibel TA
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Banypersad, Sanjay M
AU  - Banypersad SM
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Maestrini, Viviana
AU  - Maestrini V
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Barcella, William
AU  - Barcella W
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Rosmini, Stefania
AU  - Rosmini S
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Bulluck, Heerajnarain
AU  - Bulluck H
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Sayed, Rabya H
AU  - Sayed RH
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Patel, Ketna
AU  - Patel K
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Mamhood, Shameem
AU  - Mamhood S
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Bucciarelli-Ducci, Chiara
AU  - Bucciarelli-Ducci C
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Whelan, Carol J
AU  - Whelan CJ
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Herrey, Anna S
AU  - Herrey AS
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Lachmann, Helen J
AU  - Lachmann HJ
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Wechalekar, Ashutosh D
AU  - Wechalekar AD
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Manisty, Charlotte H
AU  - Manisty CH
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Schelbert, Eric B
AU  - Schelbert EB
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Kellman, Peter
AU  - Kellman P
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Gillmore, Julian D
AU  - Gillmore JD
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Hawkins, Philip N
AU  - Hawkins PN
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.).
FAU - Moon, James C
AU  - Moon JC
AD  - From Heart Hospital, London, UK (M.F., S.P., P.R., A.A.-G., T.A.T., S.M.B., V.M., 
      S.R., H.B., A.S.H., C.H.M., J.C.M.); Institute of Cardiovascular Science (M.F., 
      A.A.-G., T.A.T., S.M.B., H.B., J.C.M.) and Department of Statistical Science 
      (W.B.), University College London, UK; National Amyloidosis Centre, University 
      College London, Royal Free Hospital, London, UK (M.F., S.M.B., R.H.S., K.P., 
      S.M., C.J.W., H.J.L., A.D.W., J.D.G., P.N.H.); Bristol Heart Institute, 
      University of Bristol, UK (C.B.-D.); University of Pittsburgh School of Medicine, 
      PA (E.B.S.); and National Heart, Lung and Blood Institute, National Institutes of 
      Health, Bethesda, MD (P.K.). j.moon@ucl.ac.uk.
LA  - eng
GR  - DRF-2013-06-102/DH_/Department of Health/United Kingdom
GR  - FS/10/40/28260/BHF_/British Heart Foundation/United Kingdom
GR  - Z99 HL999999/ImNIH/Intramural NIH HHS/United States
GR  - FS/12/56/29723/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150911
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
CIN - Circulation. 2016 Mar 22;133(12):e448. PMID: 27002089
CIN - Circulation. 2016 Mar 22;133(12):e449. PMID: 27002090
CIN - Circulation. 2016 Mar 22;133(12):e450-1. PMID: 27002091
MH  - Aged
MH  - Amyloidosis/*diagnosis
MH  - Cardiomyopathies/*diagnosis
MH  - Female
MH  - Gadolinium
MH  - Humans
MH  - Image Enhancement
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Prognosis
PMC - PMC4606985
MID - NIHMS715327
OTO - NOTNLM
OT  - amyloidosis
OT  - cardiac imaging techniques
OT  - magnetic resonance imaging
OT  - prognosis
EDAT- 2015/09/13 06:00
MHDA- 2016/02/04 06:00
PMCR- 2015/10/15
CRDT- 2015/09/13 06:00
PHST- 2015/03/22 00:00 [received]
PHST- 2015/08/03 00:00 [accepted]
PHST- 2015/09/13 06:00 [entrez]
PHST- 2015/09/13 06:00 [pubmed]
PHST- 2016/02/04 06:00 [medline]
PHST- 2015/10/15 00:00 [pmc-release]
AID - CIRCULATIONAHA.115.016567 [pii]
AID - 10.1161/CIRCULATIONAHA.115.016567 [doi]
PST - ppublish
SO  - Circulation. 2015 Oct 20;132(16):1570-9. doi: 10.1161/CIRCULATIONAHA.115.016567. 
      Epub 2015 Sep 11.